The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
Open accessAbstract
Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy. The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes. More than 70% of supratentorial ependymomas are defined by highly recurrent gene fusions in the NF-κB subunit gene RELA (ST-EPN-RELA), and a smaller number involve fusion of the gene encoding the transcriptional activator YAP1 (ST-EPN-YAP1). Subependymomas, a distinct histologic variant, can also be found within the supratetorial and posterior fossa compartments, and account for the majority of tumours in the molecular subgroups ST-EPN-SE and PF-EPN-SE. Here we describe mapping of active chromatin landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma cohorts, with the goal of identifying essential super-enhancer-associated genes on which tumour cells depend. Enhancer regions revealed putative oncogenes, molecular targets and pathways; inhibition of these targets with small molecule inhibitors or short hairpin RNA diminished the proliferation of patient-derived neurospheres and increased survival in mouse models of ependymomas. Through profiling of transcriptional enhancers, our study provides a framework for target and drug discovery in other cancers that lack known genetic drivers and are therefore difficult to treat.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
Integrative analysis of 111 reference human epigenomes
Roadmap Epigenomics Consortium, Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., et al. (2015) · Nature · doi:10.1038/nature14248 · Cited by 6,368
Self-citationSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationCOSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Self-citationConvergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers
Hnisz, D., Schuijers, J., Lin, C. Y., Weintraub, A. S., Abraham, B. J., Lee, T. I., Bradner, J. E., & Young, R. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.014 · Cited by 476
Self-citation
Cited by
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Self-citationChildhood cerebellar tumours mirror conserved fetal transcriptional programs
Vladoiu, M. C., El-Hamamy, I., Donovan, L. K., Farooq, H., Holgado, B. L., Sundaravadanam, Y., Ramaswamy, V., Hendrikse, L. D., Kumar, S., Mack, S. C., et al. (2019) · Nature · doi:10.1038/s41586-019-1158-7 · Cited by 426
Self-citationHosein, A. N., Huang, H., Wang, Z., Parmar, K., Du, W., Huang, J., Maitra, A., Olson, E., Verma, U., & Brekken, R. A. (2019) · JCI Insight · doi:10.1172/jci.insight.129212 · Cited by 302
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
Pajtler, K. W., Wen, J., Sill, M., Lin, T., Orisme, W., Tang, B., Hübner, J.-M., Ramaswamy, V., Jia, S., Dalton, J. D., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1877-0 · Cited by 262
Self-citationYang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
Metadata
- Authors
- Mack, S. C., Pajtler, K. W., Chavez, L., Okonechnikov, K., Bertrand, K. C., Wang, X., Erkek, S., Federation, A., Song, A., Lee, C., Wang, X., McDonald, L., Morrow, J. J., Saiakhova, A., Sin-Chan, P., Wu, Q., Michaelraj, K. A., Miller, T. E., Hubert, C. G., Ryzhova, M., Garzia, L., Donovan, L., Dombrowski, S., Factor, D. C., Luu, B., Valentim, C. L. L., Gimple, R. C., Morton, A., Kim, L., Prager, B. C., Lee, J. J. Y., Wu, X., Zuccaro, J., Thompson, Y., Holgado, B. L., Reimand, J., Ke, S. Q., Tropper, A., Lai, S., Vijayarajah, S., Doan, S., Mahadev, V., Miñan, A. F., Gröbner, S. N., Lienhard, M., Zapatka, M., Huang, Z., Aldape, K. D., Carcaboso, A. M., Houghton, P. J., Keir, S. T., Milde, T., Witt, H., Li, Y., Li, C.-J., Bian, X.-W., Jones, D. T. W., Scott, I., Singh, S. K., Huang, A., Dirks, P. B., Bouffet, E., Bradner, J. E., Ramaswamy, V., Jabado, N., Rutka, J. T., Northcott, P. A., Lupien, M., Lichter, P., Korshunov, A., Scacheri, P. C., Pfister, S. M., Kool, M., Taylor, M. D., & Rich, J. N.
- Venue
- Nature
- Published
- 2017-12-20
- Volume
- 553
- Issue
- 7686
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2780843582
- Cited by
- 216
- References
- 9
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. https://app.cochat.ai/papers/10.1038/nature25169
- The paper
- Mack, S. C., Pajtler, K. W., Chavez, L., Okonechnikov, K., Bertrand, K. C., Wang, X., Erkek, S., Federation, A., Song, A., Lee, C., Wang, X., McDonald, L., Morrow, J. J., Saiakhova, A., Sin-Chan, P., Wu, Q., Michaelraj, K. A., Miller, T. E., Hubert, C. G., . . . Rich, J. N. (2018). Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. https://doi.org/10.1038/nature25169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.